Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

PRX003

Monoclonal antibody · developed by Prothena Biosciences

Phase 1 Most advanced trial (none active)
PRTA Developer
1 Registered trials

What is PRX003?

PRX003 is an investigational agent studied in psoriasis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Monoclonal antibody
Therapy area
Dermatology
Developer
Prothena Biosciences Limited (PRTA)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1
UNII
IYH4W60MAZ

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT02630901 Phase 1 Psoriasis Completed PRTA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Psoriasis

More from Prothena Biosciences

Follow PRTA, the company behind PRX003

See PRTA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

PRTA catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.